Status: Not yet recruiting
A Study of SRN-101 Administered Prior to Surgical Resection in Adults With Recurrent High-Grade Glioma.
SRN-101 is designed to destroys tumor cells while simultaneously activating the immune system to fight cancer. This is a first in human, single arm study to evaluate SRN-101 for the treatment of adults with recurrent high-grade glioma (rHGG) who are eligible for resection.
Participants needed: 6
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Nicholas ButowskiUpdated: Oct 8, 2026Locations: 1
Eligibility criteria
Male or female ≥ 18 years of age. [+10]
Disseminated disease or multifocal disease. [+10]